This ETF does not track a specific index. Instead, T. Rowe Price's portfolio manager hand-picks blue-chip large-cap growth stocks with strong long-term earnings growth potential. It invests the majority of its net assets in high-quality companies with growth characteristics across a range of growth sectors, including technology, health care and consumer goods.

It suits investors who prefer research-driven active stock selection over index tracking and want to invest for the long term in US blue-chip growth stocks.

It is an actively managed ETF launched by T. Rowe Price in 2020.

Based on T. Rowe Price's in-depth company analysis, the fund selects blue-chip growth companies with strong brand competitiveness and long-term earnings growth potential. It keeps portfolio turnover low and follows a long-term, buy-and-hold approach, so it is run around high-conviction holdings without frequent replacement.

• Truly active management that selects stocks through research rather than tracking an index
• Pursues a cost-efficient long-term holding strategy with low portfolio turnover

Assets under management (AUM) stand at $2.1B, and the expense ratio is 0.57% per year.

As an active ETF, TCHP carries higher fees than comparable passive growth ETFs. The key question is whether T. Rowe Price's long-standing research capabilities can make up for that fee gap.

The US large-cap growth sector has shown a long-term upward trend, driven by technological innovation and corporate earnings growth. However, shifts in the interest rate environment and valuation pressure on growth stocks have increased short-term volatility, and in such an environment, stock-selection skill becomes the key variable behind performance differences.

The US active growth ETF market is smaller than its passive counterpart, but inflows continue, driven mainly by demand from investors dissatisfied with index-tracking approaches. T. Rowe Price's long track record in asset management and brand credibility support the fund's inflow base, and the strength of inflows tends to vary with the growth-stock preference cycle.

Research-driven stock selection is the core strength, while higher fees than passive funds and dependence on the manager are the risk factors.

Comparable products in the same category as TCHP include JGRO, FBCG, NULG and LRGE. JGRO is J.P. Morgan's research-enhanced active growth ETF, while FBCG actively manages Fidelity's blue-chip growth strategy. LRGE is a large-cap growth ETF that incorporates sentiment analysis, so its strategic direction differs. Outside the comparison table, the passive IVW (iShares S&P 500 Growth ETF) and VUG (Vanguard Growth ETF) serve as benchmarks for judging whether active fees are justified.

Here are the points to review before investing in TCHP. Because it is an active ETF, you should check a combination of variables together, including the fee level, manager skill, growth stock valuations and exchange rates.

By nature, growth stocks can suffer sharp short-term declines when the interest rate environment shifts or the broader market turns risk-off. Performance relative to the market can vary with the manager's discretion, and given the nature of active strategies, long-term outperformance is not guaranteed.

It is an option worth considering for investors who want to invest in blue-chip growth stocks backed by T. Rowe Price's proven research capabilities. If fee efficiency is the priority, it is appropriate to compare it with passive growth ETFs such as IVW and VUG before deciding.